126 related articles for article (PubMed ID: 12133538)
1. Clinical significance of plasma tissue factor pathway and urokinase-type plasminogen activator system in cancer patients.
Zhao W; Wang X; Qu B; Huang X; Wang H
Chin Med J (Engl); 2002 May; 115(5):702-4. PubMed ID: 12133538
[TBL] [Abstract][Full Text] [Related]
2. Urokinase system expression in gastric carcinoma: prognostic impact in an independent patient series and first evidence of predictive value in preoperative biopsy and intestinal metaplasia specimens.
Beyer BC; Heiss MM; Simon EH; Gruetzner KU; Babic R; Jauch KW; Schildberg FW; Allgayer H
Cancer; 2006 Mar; 106(5):1026-35. PubMed ID: 16435385
[TBL] [Abstract][Full Text] [Related]
3. [Clinical study of hemostatic molecular markers expression in patients with cancer].
Wu F; Qu B; Wang XF; Yang CM; Wang HL
Zhonghua Nei Ke Za Zhi; 2004 Nov; 43(11):837-40. PubMed ID: 15634544
[TBL] [Abstract][Full Text] [Related]
4. [Expression and clinical significance of coagulate and fibrolysis factors in tissue and plasma from hepatocellular carcinoma patients].
Zhou Q; Liang LJ; Peng BG; Zhen YY
Ai Zheng; 2006 Nov; 25(11):1433-8. PubMed ID: 17094916
[TBL] [Abstract][Full Text] [Related]
5. [Study of the effect of TF/FVIIa complex on the expression of u-PAR mRNA in human ovarian cancer].
Fang J; Wei WN; Xia LH; Song SJ
Zhonghua Xue Ye Xue Za Zhi; 2004 Mar; 25(3):143-6. PubMed ID: 15182581
[TBL] [Abstract][Full Text] [Related]
6. Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis.
Shariat SF; Roehrborn CG; McConnell JD; Park S; Alam N; Wheeler TM; Slawin KM
J Clin Oncol; 2007 Feb; 25(4):349-55. PubMed ID: 17264329
[TBL] [Abstract][Full Text] [Related]
7. [Influence of overexpressed coagulant and fibrolytic components in tumor tissues on the prognosis of non-small cell lung cancer].
Chen WH; Wang C; Zhang YH; Yang YH; Zhan HY; Zhang LM
Zhonghua Yi Xue Za Zhi; 2007 Dec; 87(45):3228-32. PubMed ID: 18399120
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic efficacy of plasma urokinase-type plasminogen activator and plasminogen activator inhibitor-2 in differentiation of hepatocellular carcinoma from cirrhosis.
Song KS; Lee A; Choi JR; Kwon OH
Thromb Haemost; 1995 Sep; 74(3):864-7. PubMed ID: 8571313
[TBL] [Abstract][Full Text] [Related]
9. Tumor-specific transcription factor binding to an activator protein-2/Sp1 element of the urokinase-type plasminogen activator receptor promoter in a first large series of resected gastrointestinal cancers.
Schewe DM; Leupold JH; Boyd DD; Lengyel ER; Wang H; Gruetzner KU; Schildberg FW; Jauch KW; Allgayer H
Clin Cancer Res; 2003 Jun; 9(6):2267-76. PubMed ID: 12796395
[TBL] [Abstract][Full Text] [Related]
10. Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: an EORTC Receptor and Biomarker Group collaboration.
Grebenchtchikov N; Maguire TM; Riisbro R; Geurts-Moespot A; O'Donovan N; Schmitt M; McGreal G; McDermott E; O'Higgins N; Brünner N; Sweep CG; Duffy MJ
Oncol Rep; 2005 Jul; 14(1):235-9. PubMed ID: 15944795
[TBL] [Abstract][Full Text] [Related]
11. Increased urokinase-type plasminogen activator receptor and epidermal growth factor receptor in serum of patients with prostate cancer.
Milanese G; Dellabella M; Fazioli F; Pierpaoli E; Polito M; Siednius N; Montironi R; Blasi F; Muzzonigro G
J Urol; 2009 Mar; 181(3):1393-400. PubMed ID: 19157433
[TBL] [Abstract][Full Text] [Related]
12. Urokinase type plasminogen activator receptor is a novel prognostic factor in breast cancer.
Kim SJ; Shiba E; Taguchi T; Watanabe T; Tanji Y; Kimoto Y; Izukura M; Takai SI
Anticancer Res; 1997; 17(2B):1373-8. PubMed ID: 9137501
[TBL] [Abstract][Full Text] [Related]
13. [Expression and significance of urokinase-type plasminogen activator, its receptor, and type 2 inhibitor in giant cell tumor of bone].
Li H; Dong S; Zeng Y
Zhonghua Zhong Liu Za Zhi; 2001 Sep; 23(5):386-8. PubMed ID: 11810768
[TBL] [Abstract][Full Text] [Related]
14. Identification of markers of possible prognostic value in 57 giant cell tumors of bone.
Gamberi G; Serra M; Ragazzini P; Magagnoli G; Pazzaglia L; Ponticelli F; Ferrari C; Zanasi M; Bertoni F; Picci P; Benassi MS
Oncol Rep; 2003; 10(2):351-6. PubMed ID: 12579271
[TBL] [Abstract][Full Text] [Related]
15. Urokinase-type plasminogen activator in colorectal cancer: relationship with clinicopathological features and patient outcome.
Skelly MM; Troy A; Duffy MJ; Mulcahy HE; Duggan C; Connell TG; O'Donoghue DP; Sheahan K
Clin Cancer Res; 1997 Oct; 3(10):1837-40. PubMed ID: 9815571
[TBL] [Abstract][Full Text] [Related]
16. The urokinase-type plasminogen activator, its receptor and u-PA inhibitor type-1 affect in vitro growth and invasion of Kaposi's sarcoma and capillary endothelial cells: role of HIV-Tat protein.
Margheri F; D'Alessio S; Serratì S; Pucci M; Del Rosso A; Benelli R; Ferrari N; Noonan DM; Albini A; Fibbi G; Del Rosso M
Int J Oncol; 2005 Jul; 27(1):223-35. PubMed ID: 15942664
[TBL] [Abstract][Full Text] [Related]
17. Sensitive and specific enzyme-linked immunosorbent assay for urokinase-type plasminogen activator and its application to plasma from patients with breast cancer.
Grøndahl-Hansen J; Agerlin N; Munkholm-Larsen P; Bach F; Nielsen LS; Dombernowsky P; Danø K
J Lab Clin Med; 1988 Jan; 111(1):42-51. PubMed ID: 3121772
[TBL] [Abstract][Full Text] [Related]
18. [The plasma levels of urokinase plasminogen activator and urokinase plasminogen activator receptor and plasminogen activator inhibitor-1 in patients with different stages of liver cirrhosis following chronic hepatitis B].
Wu XR; Wang Q; Shi SS; Lu MH; Guo WD
Zhonghua Gan Zang Bing Za Zhi; 2004 Feb; 12(2):82-4. PubMed ID: 14980106
[TBL] [Abstract][Full Text] [Related]
19. Combination analysis of activator protein-1 family members, Sp1 and an activator protein-2alpha-related factor binding to different regions of the urokinase receptor gene in resected colorectal cancers.
Schewe DM; Biller T; Maurer G; Asangani IA; Leupold JH; Lengyel ER; Post S; Allgayer H
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8538-48. PubMed ID: 16361535
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of expression of urokinase-type plasminogen activator in patients with prostate cancer.
Ohta S; Fuse H; Fujiuchi Y; Nagakawa O; Furuya Y
Anticancer Res; 2003; 23(3C):2945-50. PubMed ID: 12926141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
